Verus International, Inc. (VRUS)

0.02
OTC Markets
Prev Close 0.02
Day Low/High 0.02 / 0.02
52 Wk Low/High 0.00 / 0.04
Exchange OTC Markets
Shares Outstanding 2290.45B
Market Cap 50.39M
Div & Yield N.A. (N.A)

Latest News

VERUS INTERNATIONAL SIGNS $13.5 MILLION CREDIT INSURANCE POLICY; SELLS OUT FIRST RUN OF MLB ICE CREAM

VERUS INTERNATIONAL SIGNS $13.5 MILLION CREDIT INSURANCE POLICY; SELLS OUT FIRST RUN OF MLB ICE CREAM

Gaithersburg, MD, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc.

VERUS INTERNATIONAL ANNOUNCES $500,000 LINE OF CREDIT WITH THE COLUMBIA BANK, N.A.

VERUS INTERNATIONAL ANNOUNCES $500,000 LINE OF CREDIT WITH THE COLUMBIA BANK, N.A.

Gaithersburg, MD, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc.

VERUS INTERNATIONAL SIGNS $605,000 NOTE; INCREASES FUNDED BACKLOG

VERUS INTERNATIONAL SIGNS $605,000 NOTE; INCREASES FUNDED BACKLOG

Gaithersburg, MD, July 08, 2019 (GLOBE NEWSWIRE) -- Verus International, Inc. ("Verus" or the "Company") (OTC:VRUS) is pleased to announce that it has strengthened its capital structure via a $605,000 fixed-rate convertible note from Eagle Equities, LLC.

Two Months Into 2019, It's Time To Take Stock of My Winners and Losers

Two Months Into 2019, It's Time To Take Stock of My Winners and Losers

And the winners so far outnumber the losers among the six stocks that include a cannabis company, a couple financial giants and two oil plays.

What to Buy in the Selloff

Here are several themes that are still working -- and now you can get in at a bargain.

Corporate Leaders Receive Twelfth Annual Emerald Asset Management “E-3 Awards”

Corporate Leaders Receive Twelfth Annual Emerald Asset Management “E-3 Awards”

The Chief Executive Officers of MWI Veterinary Supply, Inc. (NASDAQ: MWIV) and Campus Crest Communities, Inc.

Gilead Sciences Completes Acquisition Of Pharmasset, Inc.

Gilead Sciences Completes Acquisition Of Pharmasset, Inc.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Royal Merger Sub II Inc.

Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Pharmasset, Inc.

Gilead Sciences Completes Tender Offer For All Outstanding Shares Of Pharmasset, Inc.

Gilead Sciences, Inc. (Nasdaq:GILD) today announced the successful completion of the tender offer by its wholly-owned subsidiary, Royal Merger Sub II Inc.

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Idenix Pharma's Hep C Drug Safe But Slow (And Ready For Sale)

Idenix shares surge as the concerns about the safety of its hepatitis C drug appear to be lifted.

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

Hep C Deal-A-Palooza: Bristol-Myers Buys Inhibitex for $2.5 Billion

The arms race to develop the next generation of hepatitis C therapies is escalating.

Inhibitex Shares Whipsawed by Cautious Analyst Comment

Inhibitex Shares Whipsawed by Cautious Analyst Comment

Investors are nervous about the safety of Inhibitex's hepatitis C drug ahead of an important safety check.

5 Big Surprise Stock Winners of 2011

5 Big Surprise Stock Winners of 2011

A year ago, you might not have predicted that these stocks would soar in 2011.

'Fast Money' Recap: Beaten-Up Financials Eyed

'Fast Money' Recap: Beaten-Up Financials Eyed

Traders discuss the markets and the one sector that is actually still getting attention: Beaten-up financials.

Analysts' Actions: GRPN, VRUS, MU, CVC

Analysts' Actions: GRPN, VRUS, MU, CVC

Here are today's top research calls.

Five Drug Stock Winners of 2011

Five Drug Stock Winners of 2011

Investors did well in 2011 to own these biotech and drug stocks, all of which more than doubled in value.

Pharmasset Inc. (VRUS): Today's Featured Drugs Loser

Pharmasset Inc. (VRUS): Today's Featured Drugs Loser

Pharmasset was a leading decliner within the drugs industry, falling $4.04 (-3.2%) to $123.75 on heavy volume.

Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector

Hep C Drug Panic! Pharmasset Stumble Ripples Through Sector

Inhibitex, Idenix Pharma shares suffer as Pharmasset discloses liver problems with one of its hepatitis C drugs.

10 Best Mutual Funds of 2011 You've Never Heard Of

10 Best Mutual Funds of 2011 You've Never Heard Of

What stock market turmoil? These managers have beaten their benchmarks over many years.

A Play Off Biotech Volatility

A Play Off Biotech Volatility

These Hep C drugmakers have taken a pummeling, so I'm entering a couple of aggressive trades here.

These May Well Be Euro-Crisis-Immune

These May Well Be Euro-Crisis-Immune

These speculative biotech issues have the power to defy gravity in the worst markets.

Vertex Makes CEO Change Amidst Efforts to Diversify Beyond Hepatitis C

Vertex Makes CEO Change Amidst Efforts to Diversify Beyond Hepatitis C

Matt Emmens retires as Vertex's CEO, replaced by board member Jeff Leiden.

The Best Biotech CEO of 2011 Is ...

The Best Biotech CEO of 2011 Is ...

TheStreet's readers make a surprising selection, prompting analyst Adam Feuerstein to call an audible.

Best Biotech CEO of 2011 -- Vote Here

Best Biotech CEO of 2011 -- Vote Here

There are five nominees, and the winner will be chosen in a week.

Bull & Lifshitz, LLP Announces Investigation Of Pharmasset, Inc.

Bull & Lifshitz, LLP Announces Investigation Of Pharmasset, Inc.

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmasset, Inc.

Pharmasset Inc. (VRUS): Today's Featured Drugs Loser

Pharmasset Inc. (VRUS): Today's Featured Drugs Loser

Pharmasset Inc was a leading decliner within the drugs industry, falling $1.44 (-1.1%) to $130.99 on heavy volume.

Biotech Stock Mailbag: 2011 Report Card

Biotech Stock Mailbag: 2011 Report Card

Biotech columnist Adam Feuerstein looks back at a year's worth of reader questions and concerns about biotech and drug stocks.

Stocks to Watch: HP, Netflix, Hormel

Stocks to Watch: HP, Netflix, Hormel

Hewlett-Packard shares are lower in premarket trading Tuesday after the computer maker said it was 'cautious' about 2012.

The Law Firm Of Weiss & Lurie Investigates Pharmasset, Inc.

The Law Firm Of Weiss & Lurie Investigates Pharmasset, Inc.

Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of ...